A double-blind, placebo-controlled, multicenter study of 90 patients found that intramuscular ALC (500 mg twice daily for 14 days followed by oral ALC 1,000 mg twice daily for 42 days) produced significantly greater reduction in pain compared with placebo in the efficacy-evaluable population (P=0.022).[4] An open cohort study of 21 HIV-positive patients with established ATN treated with oral ALC 1,500 mg twice daily for up to 33 months demonstrated remarkable nerve regeneration: mean immunostaining area for small sensory fibers increased 100% in epidermis and 133% in dermis after 6 months, with neuropathic grade improving in 76% of patients.[5] However, a subsequent open-label study found that while ALC therapy coincided with improvements in subjective measures of pain, changes were not observed in objective measures of intra-epidermal nerve fiber density or mitochondrial DNA levels.[6] Context with Other Treatments: Second-line or adjunctive therapy for ATN
L- ,
*Statements on this website have not been evaluated by the FDA
Scheen AJ, Delanaye P
While most cases of delayed cutaneous hypersensitivity have been recorded in patients who received the Moderna vaccine, a few cases have been reported by recipients of the Pfizer vaccine, says Esther Freeman, M.D., Ph.D., director of Global Health Dermatology at Massachusetts General Hospital and principal investigator for the global COVID-19 Dermatology Registry
Effective Treatments Can Clear the Way for Remission Often, psoriasis remission may follow a successful course of treatment
